Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib

Publication date: Available online 1 October 2020Source: European UrologyAuthor(s): Konrad H. Stopsack
Source: European Urology - Category: Urology & Nephrology Source Type: research